Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants
View ORCID ProfileGebremedhin B. Gebretekle, Man Wah Yeung, View ORCID ProfileRaphael Ximenes, View ORCID ProfileAlexandra Cernat, View ORCID ProfileAlison E. Simmons, April Killikelly, View ORCID ProfileWinnie Siu, View ORCID ProfileEllen Rafferty, View ORCID ProfileNicholas Brousseau, View ORCID ProfileMatthew Tunis, View ORCID ProfileAshleigh R. Tuite
doi: https://doi.org/10.1101/2024.03.21.24304675
Gebremedhin B. Gebretekle
1Centre for Immunization Programs, Public Health Agency of Canada, Ottawa, ON
PhDMan Wah Yeung
1Centre for Immunization Programs, Public Health Agency of Canada, Ottawa, ON
MScRaphael Ximenes
1Centre for Immunization Programs, Public Health Agency of Canada, Ottawa, ON
PhDAlexandra Cernat
1Centre for Immunization Programs, Public Health Agency of Canada, Ottawa, ON
2Health Policy PhD Program, Faculty of Health Sciences, McMaster University, Hamilton, ON
MScAlison E. Simmons
1Centre for Immunization Programs, Public Health Agency of Canada, Ottawa, ON
3Dalla Lana School of Public Health, University of Toronto, Toronto, ON
MPHApril Killikelly
1Centre for Immunization Programs, Public Health Agency of Canada, Ottawa, ON
PhDWinnie Siu
1Centre for Immunization Programs, Public Health Agency of Canada, Ottawa, ON
MDEllen Rafferty
4Institute of Health Economics, Edmonton, AB
5Department of Medicine, Faculty of Medicine and Dentistry, University of Alberta, Edmonton, AB
Nicholas Brousseau
6Biological Risks Unit, Institut national de santé publique du Québec, Québec, Canada
7Department of Social and Preventive Medicine, Université Laval, Québec, Canada
MDMatthew Tunis
1Centre for Immunization Programs, Public Health Agency of Canada, Ottawa, ON
PhDAshleigh R. Tuite
1Centre for Immunization Programs, Public Health Agency of Canada, Ottawa, ON
3Dalla Lana School of Public Health, University of Toronto, Toronto, ON
PhD MPHData Availability
All data produced in the present work are contained in the manuscript
Posted March 24, 2024.
Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants
Gebremedhin B. Gebretekle, Man Wah Yeung, Raphael Ximenes, Alexandra Cernat, Alison E. Simmons, April Killikelly, Winnie Siu, Ellen Rafferty, Nicholas Brousseau, Matthew Tunis, Ashleigh R. Tuite
medRxiv 2024.03.21.24304675; doi: https://doi.org/10.1101/2024.03.21.24304675
Cost-effectiveness of RSVpreF vaccine and nirsevimab for the prevention of respiratory syncytial virus disease in Canadian infants
Gebremedhin B. Gebretekle, Man Wah Yeung, Raphael Ximenes, Alexandra Cernat, Alison E. Simmons, April Killikelly, Winnie Siu, Ellen Rafferty, Nicholas Brousseau, Matthew Tunis, Ashleigh R. Tuite
medRxiv 2024.03.21.24304675; doi: https://doi.org/10.1101/2024.03.21.24304675
Subject Area
Subject Areas
- Addiction Medicine (325)
- Allergy and Immunology (635)
- Anesthesia (168)
- Cardiovascular Medicine (2418)
- Dermatology (208)
- Emergency Medicine (382)
- Epidemiology (11831)
- Forensic Medicine (10)
- Gastroenterology (705)
- Genetic and Genomic Medicine (3792)
- Geriatric Medicine (353)
- Health Economics (641)
- Health Informatics (2426)
- Health Policy (943)
- Hematology (344)
- HIV/AIDS (795)
- Medical Education (372)
- Medical Ethics (105)
- Nephrology (404)
- Neurology (3548)
- Nursing (200)
- Nutrition (531)
- Oncology (1844)
- Ophthalmology (541)
- Orthopedics (223)
- Otolaryngology (287)
- Pain Medicine (234)
- Palliative Medicine (68)
- Pathology (450)
- Pediatrics (1045)
- Primary Care Research (425)
- Public and Global Health (6212)
- Radiology and Imaging (1302)
- Respiratory Medicine (839)
- Rheumatology (381)
- Sports Medicine (327)
- Surgery (409)
- Toxicology (51)
- Transplantation (174)
- Urology (148)